Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q3 2023 Earnings Presentation
12 slides from Adc Therapeutics Sa's earnings presentation, Nov 7, 2023
Slide 1: 3Q 2023 Earnings Call
3Q 2023 Earnings Call November 7, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Introduction 02 Kristen Harrington-Smith Commercial Highlights Chief Commercial Officer 03 Mohamed Zaki Clinical Highlights Chief Medical Officer Pepe Carmona Financial Update 04 Chief Financial Officer 3
Slide 4: Recent Highlights
Recent Highlights ▪ 3Q 2023 net product sales: $14.3M, reflects extended disruption following restructuring of commercial organization, an increasingly competitive environment and higher gross-to-net deductions ZYNLONTA® ▪ Expect to see growth in the coming quarters (loncastuximab ▪ Partner Mitsubis
Slide 5: ZYNLONTA Net Sales: $14.3M in 3Q 2023
ZYNLONTA Net Sales: $14.3M in 3Q 2023 New go-to-market Average call volumes model ▪ Q3 sales impacted by: Evolving market dynamics • Extended period of disruption following the restructuring of the commercial model • Increasingly competitive environment • Higher gross-to-net sales deductions ▪ Call
Slide 6: Clear Role for ZYNLONTA in Dynamic DLBCL Market
Clear Role for ZYNLONTA in Dynamic DLBCL Market Academic Community ▪ ZYNLONTA has an important role in academic setting ▪ Majority of the opportunity for ZYNLONTA ▪ ZYNLONTA well positioned for patients who are not ▪ Well-suited clinical profile: highly effective suitable candidates for bispecifics/
Slide 7: Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy
Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy Patient population 2L DLBCL Relapsed/refractory B-cell Non-Hodgkin Lymphoma ASCT ineligible – DLBCL, FL, MZL Study summary Phase 1 trial of ZYNLONTA in combination with glofitamab Phase 3 confirmatory trial in comb
Slide 8: Prioritized Pipeline Advancing with Data in 1H 2024
Prioritized Pipeline Advancing with Data in 1H 2024 ▪ Dose escalation progressing in Phase 1b study exploring monotherapy treatment in patients with ADCT-601 sarcoma and NSCLC; maximum tolerated dose has not yet been reached Targeting AXL ▪ Based on preclinical data, adding pancreatic cohort with en
Slide 9: 3Q 2023 Financial Update (in $ millions)
3Q 2023 Financial Update (in $ millions) Cash runway expected to extend into mid-2025 based on current business plan Balance Sheet September 30, 2023 Cash and cash equivalents $310.4 IFRS Non-IFRS (Adjusted)* Statement of Operations 3Q 2023 % vs. 3Q 2022 3Q 2023 % vs. 3Q 2022 Product Revenue, Net 14
Slide 10: Multiple Value-Driving Catalysts Expected Through 2024
Multiple Value-Driving Catalysts Expected Through 2024 2H 2023 1H 2024 2024 ❑ ZYNLONTA: European launch by ❑ LOTIS-7: Initial data from study of ZYNLONTA in ❑ Complete enrollment of partner Sobi in 2Q 2023 combination with novel bispecifics LOTIS-5 study ❑ ZYNLONTA: Updated safety lead-in ❑ ADCT-601
Slide 11: 3Q 2023 Earnings Call
Earnings Call 2 TH ERAPEUTICS iting Science. Inspiring Hope.
Slide 12: Reconciliation of IFRS to Non-IFRS Adjustments
Reconciliation of IFRS to Non-IFRS Adjustments in KUSD 3Q 2023 3Q 2022 Net loss (IFRS) (47,807) (50,608) Adjustments: Share-based compensation expense - R&D (i) 157 4,309 Share-based compensation expense - S&M (i) 161 1,876 Share-based compensation expense - G&A (i) 1,765 8,380 Convertible loans, de